|
|
| Line 40: |
Line 40: |
| [[Category:Cardiovascular Drugs]] | | [[Category:Cardiovascular Drugs]] |
| [[Category:Drugs]] | | [[Category:Drugs]] |
|
| |
| {| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0";
| |
| ! style="padding: 0 5px; font-size: 100%; background:#F8F8FF" align=center | '''''[[Bivalirudin|{{fontcolor|#6C7B8B|Bivalirudin}}]]'''''
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | ANGIOMAX<sup>®</sup> FDA Package Insert
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin indications and usage|Indications and Usage]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin dosage and administration|Dosage and Administration]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin dosage forms and strengths|Dosage Forms and Strengths]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin contraindications|Contraindications]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin warnings and precautions|Warnings and Precautions]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin adverse reactions|Adverse Reactions]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin drug interactions|Drug Interactions]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin use in specific populations|Use in Specific Populations]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin overdosage|Overdosage]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin description|Description]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin clinical pharmacology|Clinical Pharmacology]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin nonclinical toxicology|Nonclinical Toxicology]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin clinical studies|Clinical Studies]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin how supplied storage and handling|How Supplied/Storage and Handling]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin patient counseling information|Patient Counseling Information]]
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Bivalirudin labels and packages|Labels and Packages]]
| |
| |-
| |
| ! style="padding: 0 5px; font-size: 85%; background:#F5F5F5" align=left | Clinical Trials on Bivalirudin
| |
| |-
| |
| ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [http://clinicaltrials.gov/search/open/condition={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}} ClinicalTrials.gov]
| |
| |-
| |
| |}
| |